Back to All Events

Board Chair perspectives on Agomab's $200m NASDAQ IPO

A Directors' Forum session on board chair perspectives on Agomab's NASDAQ IPO.

Previous
Previous
4 February

M&A Exit vs. Venture Financing in the current Climate

Next
Next
24 April

Learnings from Agomab's recent $208m NASDAQ IPO